Neurodyn Inc. acquires Memogain for Dementia in Alzheimer’s Disease

11-Sep-2013 - Neurodyn Inc. announced that it has acquired from Galantos Pharma GmbH, Mainz, Germany all assets related to their Alzheimer’s prescription drug candidate – Memogain®. Memogain® has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in ...

Galantos Pharma Raises € 4.4 Million to Advance its Alzheimer's Dementia Strategy

05-May-2010 - Galantos Pharma announced the successful finalization of its C financing round to bring its leading compound Memogain® for Alzheimer’s Dementia (AD) into the clinic and to develop novel neuroprotective AD compounds. The investors VRP (Rhineland Palatinate Fund), KfW (German State Bank), FIB ...

Galantos Pharma Receives Research Grant

Expansion of technology platform

29-May-2008 - Galantos Pharma GmbH announced that it has been granted EUR 366.000 from Investitions- und Strukturbank Rheinland-Pfalz (ISB) GmbH, the investment and economic development bank of the German federal state of Rheinland-Pfalz. The grant was awarded under the technology development program of the ...

Galantos Pharma Selects Candidate for Clinical Development in Alzheimer's Disease

Milestone triggers payment of last tranche of Series B financing round

28-Mar-2008 - Galantos Pharma GmbH, a biopharmaceutical company developing natural product derivatives to treat Alzheimer's disease (AD) announced that it has selected a candidate molecule, which is expected to move into clinical development in Alzheimer's disease (AD) in 2009. The selected molecule is a ...